Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disorder primarily characterized by motor neuron degeneration and muscle paralysis.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease defined by a progressive, selective loss of upper motor neurons (MN) in the motor cortex and lower motor neurons in the spinal cord [1] [2] [3] . The degeneration of motor nerves is accompanied by extensive denervation of skeletal muscle and muscular weakness or atrophy, leading to paralysis and ultimately death [1] [2] [3] . The mechanisms of MN degeneration in ALS remain unresolved. Abnormal protein aggregation and folding was hypothesized to be one of the major reasons accounting for ALS [4] . Approximately 90% of ALS cases are sporadic, with the remaining 10% of cases being familial. The mutations in the cytoplasmic Cu/Zn superoxide dismutase 1 (SOD1) gene account for approximately 12% of familial ALS cases [5] . A high-copy SOD1 (G93A) transgenic mouse line is commonly used to model ALS and recapitulates much of the pathophysiology of the human disease, including progressive MN degeneration, muscle atrophy, motor deficits, and reduced lifespan [6] .
Although MN degeneration in the central nervous system (CNS) is the major pathological characteristic of ALS and has received the most attention, other cell types or tissues beyond the CNS are increasingly accepted to play active roles in ALS [7] . The involvement of skeletal muscle has been the subject of a number of studies conducted on patients and related animal models. Skeletal muscle abnormalities were usually regarded as secondary to the disease mechanisms [8, 9] . However, a large body of evidence demonstrated the importance of skeletal muscle in initiating and contributing to the degeneration of MNs in ALS pathology [7, [10] [11] [12] . A study showed skeletal muscle-restricted expression of human SOD1 is sufficient to cause MN degeneration in mice [10] . In contrast, specific neuronal or astrocytic expression of mutant SOD1 in transgenic animals did not result in MN degeneration, clearly negating neurons or astrocytes as the sole mediators of ALS pathology [13] [14] [15] . These results demonstrate a causal role of skeletal muscle in ALS and suggest the possibility that skeletal muscle is a key factor for the study of ALS pathogenesis and potential therapy.
Previous studies demonstrated some skeletal muscle-specific molecular changes for ALS [11, 16] . Muscle fiber-specific up-regulation of the amyloid precursor protein (APP) has been shown to occur in both SOD1 mutant mice, as well as in human ALS cases before the appearance of clinical abnormalities [11] . Moreover, genetic ablation of APP significantly improved multiple disease parameters and ameliorated disease progression in ALS mouse models [17] .
These findings further indicate that the pathological events that occur locally in the skeletal muscle contribute to the CNS impairment, and reversal of these changes can alleviate the corresponding lesion in the CNS. APP and its processing products are usually involved in Alzheimer's disease (AD) [18] .
Mutations in APP are associated with the familial form of AD. β-amyloid protein (Aβ), a cleavage product of APP, accumulates at high levels in the brain in AD, which constitutes the typical pathological feature of this disease.
Overproduction or aggregation of Aβ in the brain is a primary cause of AD [19] .
In this process, APP is cleaved by β-secretase to generate amyloidogenic carboxyterminal fragments (βCTP), which is further cleaved by γ-secretase to generate Aβ [18, 19] . The similar changes in APP expression or processing in the affected tissues in AD or ALS suggest interesting parallels among these neurodegenerative disorders. Although elevated levels of APP in ALS muscle have been reported, whether and how APP processing in ALS skeletal muscle changes are still unclear. Because APP cleavage products are usually involved in the pathological process leading to neuronal degeneration, we here examined the changes in the expression of APP β-secretase processing products and enzyme in the skeletal muscle of mouse and pig models of ALS. 
SOD1 mutant ALS pig models showed elevated β-secretase processing of APP in skeletal muscle
We have established an ALS pig model harboring a human SOD1 transgene with a G93A mutation [21] . To investigate the changes in APP processing in the pig model, the gastrocnemii of ALS and WT pigs were assayed for the related protein levels at the age of 8 months when the motor deficit was significant in the ALS pigs. Western blots showed significantly greater βCTF and BACE1 expression in the muscle of ALS pigs than in that of WT pigs, suggesting that the β-secretase processing of APP was enhanced in ALS pig models ( Figure 6A ). However, unlike in the mouse model, the level of full-length APP was not elevated in the muscle of ALS pigs, nor could the 22-kd fragment be observed in ALS pig muscle. IHC using antibody 2454 recognizing human/pig Aβ demonstrated significantly greater immunoreactivity in the skeletal muscle fibers of ALS pigs than in those of WT pigs ( Figure 6B ).
Since IHC staining is reportedly negative for full-length APP in skeletal muscle fibers of WT animals [17] , and no up-regulated expression of full-length APP was observed in ALS pig muscle by Western blot, the positive signal may represent the up-regulated expression of the Aβ-containing CTF. We further confirmed these results by staining the skeletal muscle fibers using another antibody, MOAB-2, which specifically recognizes human/pig Aβ but not full-length APP. A similar staining pattern was observed in the skeletal muscle fibers of ALS pigs, showing significantly greater β-secretase processing of APP than in the WT animals ( Figure 6C ). BACE1 IHC also demonstrated greater expression levels in ALS pig muscles than in WT muscles. Moreover, βCTF and BACE1 positive staining was mainly limited to atrophic muscle fibers ( Figure 6D ). Double immunofluorescence labeling showed co-localization of βCTF and BACE1 immunoreactivity in the ALS muscle fibers (Figure 7) .
DISCUSSION
This study provides the first demonstration that β-secretase processing of APP is significantly elevated in the skeletal muscle of ALS animal models.
These observations extend the previous report of increased APP expression in the skeletal muscle of ALS patients and mouse models. The elevation in APP processing preceded the onset of disease signs in ALS mice by as early as 20 days, implying that APP processing is important for triggering other physical signs, including neuronal lesion and skeletal muscle paralysis. In addition to βCTF, we reproducibly detected a 22-kd CTF of APP in the skeletal muscle of ALS mice but not WT mice. The antibody recognizing Aβ also detected this fragment, indicating that the 22-kd CTF is a longer amyloidogenic processing product of APP. Previous studies reported the existence of the Aβ-containing 22-kd CTF in human platelets [22] , brain microvessels [23] , transfected 293 cells [24, 25] , and human umbilical vein endothelial cells [24] . The enhancement of βCTF and 22-kd CTF levels in skeletal muscle is an evident early pathological event in ALS mouse models, hence could be potential therapeutic targets.
The roles of APP processing or cleavage products in the pathogenesis of ALS have been implicated in several studies [26] [27] [28] [29] . SOD1 mutant ALS mouse models treated intraventricularly with a monoclonal antibody that blocks the β-secretase cleavage site on APP at a presymptomatic stage (70 or 90 days) resulted in a decrease in the levels of soluble APP-β and a delay in disease onset and deterioration [27] . In another study, over-expression of βCTF led to the earlier onset of motor symptoms associated with ALS [28] .
These reports combined with our observations demonstrate that APP cleavage products might contribute to the degeneration in ALS, and early inhibition of the APP process may ameliorate disease progression. Because the disease in skeletal muscle is an initiating causal pathological process in ALS, not merely secondary neurogenic atrophy, and elevation of APP processing is a muscle-specific early event in ALS pathology, related studies should focus on skeletal muscle rather than only on the CNS. A strategy for an APP processing intervention in skeletal muscle needs to be developed to evaluate its therapeutic potential for ALS.
In this study, the change in β-secretase processing of APP is manifested by an enhanced expression of βCTF and BACE1. However, we have been unsuccessful in detecting Aβ in skeletal muscle by immunoblot or ELISA (data not shown). Whether the failure to detect Aβ peptide reflects a high turnover or inefficient production of Aβ peptide in skeletal muscle is presently unknown.
Similarly, soluble Aβx-40 and Aβx-42 in muscle tissue from WT and ALS mice were reportedly undetectable by ELISA [17] . Indeed, the detection of Aβ peptide (Aβ monomer) in skeletal muscle with immunoblot seems to be difficult at present. Sporadic inclusion-body myositis (s-IBM) is a muscle disease characterized by accumulation of Aβ within muscle fibers. However, immunoblot assay did not detect Aβ monomers in s-IBM muscle [29] . In another study on transgenic mice over-expressing βCTF, a high level of βCTF was detected, but Aβ was difficult to detect with an immunoblot assay in the skeletal muscle and many other peripheral tissues of the transgenic mice [30] .
These findings indicate the need for the development of a more sensitive approach to detect the Aβ monomer in skeletal muscle. Furthermore, the Aβ level in neurons of the lumber spinal cord of ALS patients and mouse models was reportedly enhanced [17, 31] , whereas our result clearly showed no enhancement of APP β-secretase processing in the spinal cord and brain compared with that in WT animals, raising concerns that increased Aβ deposition may not necessarily be related to the increased β-secretase processing of APP.
In regard of the accumulated βCTF as we observed, the toxicity of βCTF accumulation has been confirmed in other studies [32, 33] . A triple transgenic AD mouse model shows an early accumulation of βCTF in the brain, and the anatomical lesions in the brain is related with βCTF levels [32] . Another paper documents that βCTF, rather than Aβ, causes memory deficits in a mouse model of dementia [33] . In the present work, we observed a similar early and age-dependent accumulation of βCTF in the skeletal muscle of ALS models, further suggesting its implication as an early and key contributor of the neurodegenerative process taking place in the animal models.
We also observed a similar change in APP processing in skeletal muscle of pig models harboring mutant SOD1 expression. The pig models have been well characterized in pathological and behavioral features as an ideal large animal model for ALS [21] . Due to the anatomical, physiological, and genetic similarities between humans and pigs, pigs are considered to be better animal models than rodents to resemble human disease; therefore, the outcome from pig models might be easily translated to the clinic [34] . The elevated APP β-secretase processing in skeletal muscles of both mouse and pig models implies that the aberrant APP processing in skeletal muscle is a general pathological feature of ALS. Taken together, amyloidogenic APP CTF and BACE1 were selectively elevated in the skeletal muscles of ALS mouse and pig models. APP β-secretase processing in the skeletal muscle may be a potential target for the development of a disease-modifying approach for ALS.
MATERIALS AND METHODS

Animals
Transgenic mice harboring a high copy number of the hSOD1 (G93A) transgene [B6SJL-Tg(SOD1-G93A)1Gur/J], as reported by Gurney et al., were used in this study [6] . The breeding pairs were purchased from The Jackson Laboratory, and the hemizygous transgenic progeny were maintained by mating the transgenic males with F1 hybrid wild-type females. The progeny were genotyped by PCR using genomic DNA isolated from the tail after birth as previously described [6] . The transgenic pigs used in this study harbored an hSOD1 (G93A) transgene and were reported previously [21] . All experiments were performed in accordance with the guidelines for animal experiments of the Department of Science and Technology of Guangdong Province, China, and approved by the animal research committee of the Guangzhou Institutes of Biomedicine and Health.
Western blot
For Western blotting, tissue samples were homogenized in RIPA buffer and centrifuged at 16,000 g at 4 °C for 30 minutes. Supernatants were collected and the protein concentration was quantified using a Pierce BCA protein assay kit (Thermo Scientific). Lysates were subjected to SDS polyacrylamide gel electrophoresis, followed by immunoblotting onto a polyvinylidene fluoride membrane (Millipore). Membranes were blocked with 5% non-fat dry milk in TBST for 2 hours and incubated overnight at 4 °C with the primary antibodies shown in Table 1 . After the membranes were washed with TBST, they were further incubated with a secondary HRP-conjugated goat anti-mouse or rabbit IgG antibody for 60 minutes at room temperature and imaged using a SuperSignal West Pico enhanced chemiluminescence kit (Thermo Scientific). The actin antibody (sc-47778, Santa Cruz) was used as a loading control.
Immunohistochemistry
The skeletal muscles were fixed with 4% buffered paraformaldehyde for at least 48 h. The tissues were then dissected, embedded in paraffin wax, cut in cross-section, and mounted on a slide. Sections were deparaffinized in xylene and rehydrated in a graded series of ethanol. Antigen retrieval was performed in a 1 M citrate buffer (pH = 6.0) bath at 90-100 °C for 20 min. Sections were blocked with 5% goat serum in PBST for 1 hour at room temperature, stained with the indicated primary antibodies overnight at 4 °C, and visualized using a VECTASTAIN ABC detection systems (Vector Laboratories). Nuclei were counterstained with hematoxylin. Finally, sections were dehydrated in graded ethanol, cleared in xylene, and then coverslipped with Permount.
Double immunofluorescence
Double immunofluorescence staining was used to examine the co-distribution of APP β-secretase cleavage products and BACE1 in the same sample. After antigen retrieval, tissue sections were incubated with MOAB-2 and BACE1 primary antibodies, followed by incubation with Alexa Fluor 488-labeled goat anti-mouse IgG and Alexa Fluor 594-labeled goat anti-rabbit IgG secondary antibodies (Invitrogen). DAPI was used to label nuclear DNA.
The slides were analyzed by fluorescence microscopy (Olympus).
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